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Abstract: Damage to the genetic material can affect cellular function in many ways. Therefore, maintenance of the ge-
netic integrity is of primary importance for all cells. Upon DNA damage, cells respond immediately with proliferation ar-
rest and repair of the lesion or apoptosis. All these consequences require recognition of the lesion and transduction of the 
information to effector systems. The accomplishment of DNA repair, but also of cell cycle arrest and apoptosis further-
more requires protein-protein interactions and the formation of larger protein complexes. More recent research shows that 
the formation of many of these aggregates depends on post-translational modifications. In this article, we have summa-
rized the different cellular events in response to a DNA double strand break, the most severe lesion of the DNA.  
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INTRODUCTION 
  The integrity of cellular DNA is threatened every day by 
exogenous factors like UV-light, ionizing radiation or envi-
ronmental and therapeutic chemicals, as well as by endoge-
nous conditions such as DNA replication, meiotic recombi-
nation or programmed rearrangements [reviewed in: 1-4]. 
These DNA lesions can result in somatic mutations, cell 
death, genomic instability and carcinogenesis. Accordingly, 
maintenance of genomic integrity represents one of the most 
important challenges for cellular organisms. To ensure func-
tionality despite recurring insults, cells have developed sev-
eral strategies to handle DNA lesions which are in principle 
prohibition of further cell divisions, repair of the lesions and 
elimination of cells with damaged DNA.  
  The repair of DNA lesions is a complex process. Moreo-
ver, diverse damages of the DNA that result from exposure 
to various adverse agents are fixed by different repair pro-
grams. Single strand breaks and damaged nucleotides that 
can result from oxidation, alkylation, hydrolysis, deamina-
tion or exposure to ionizing rays are replaced through base 
excision repair (BER), a mechanism that uses the sister 
strand as a template to direct de novo synthesis of the dam-
aged strand around the lesion [reviewed in: 5]. Photopro-
ducts and bulky DNA adducts that result e.g. from covalent 
binding of chemicals to DNA bases or exposure to UV-light 
are fixed by the nucleotide excision repair (NER) pathway 
[reviewed in: 6]. The mismatch repair (MMR) pathway, on 
the other hand, eliminates mispaired nucleotides that can 
arise during DNA replication and recombination [reviewed 
in: 7]. Ionizing radiation and replication in the presence of  
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DNA lesions lead to the generation of DNA double strand 
breaks (DSBs), which are mainly fixed by two different re-
pair mechanisms: homologous recombination (HR) and non-
homologous endjoining (NHEJ).  
  While relatively rare, DSBs are the most severe DNA 
lesion since repair is difficult und the original state is seldom 
fully reconstituted. Moreover, we still understand only little 
about the response to DSBs, although a large number of the 
proteins that are involved have been identified. However, it 
is still ill-defined how these proteins are recruited to the site 
of the lesion and how the different factors interact and com-
municate with each other to repair the damage and to guard 
the genome. In this review we will summarize the cellular 
response to DSBs. Hereby, we will particularly focus on 
signal transduction processes that occur during DNA damage 
recognition and repair.  
  Post-translational modifications of existing molecules 
play an important role in the cellular response to DSBs since 
they provide a means to alter the activity of a given protein 
without the necessity of de novo protein synthesis. Thus, the 
properties of a protein can be changed rapidly and without 
the need to transcribe damaged DNA which could be grossly 
hindered by the lesion or may result in non-functional pro-
tein products. While already addition or removal of small 
chemical groups modifies the characteristics of a target pro-
tein dramatically, small proteins of the family of ubiquitin-
like proteins are also frequently attached to molecules in-
volved in different cellular processes, to alter their activities 
or to extend their repertoire of protein-protein interactions. 
The most common post-translational modifications, also 
during the response to DSBs, are phosphorylation, acetyla-
tion, methylation, ubiquitination, SUMOylation and NED-
Dylation. All these modifications are reversible and, accord-
ingly, regulated by two types of enzymes. Phosphorylation 
is, for example, performed by kinases that covalently link a Regulation of the DNA Damage Response  Current Genomics, 2010, Vol. 11, No. 3    185 
phosphate group onto a serine, threonine or tyrosine of the 
target protein [reviewed in: 8]. Phosphatases reverse this 
alteration by removing the phosphate group [reviewed in: 9]. 
Phosphorylation frequently results in a conformational 
change of the modified protein due to the introduction of a 
negative charge and may result in activation or inactivation 
of an enzyme. Alternatively, it can alter the capacity of a 
target protein to associate with other cellular factors [re-
viewed in: 8]. The property of a protein can also be changed 
by reversible addition of acetyl- or methyl-groups, a process 
that is similar to the attachment of phosphate groups [re-
viewed in: 10, 11]. Acetyl-groups are attached to lysine resi-
dues in the target protein by acetyltransferases and removed 
by deacetylases [reviewed in: 10]. Lysines as well as argini-
nes can further be modified by addition of a methyl-group, 
which is catalyzed by methyltransferases [reviewed in: 11]. 
The functional outcome of acetylation and methylation de-
pends on the target protein and the position of the acety-
lated/methylated lysine in the molecule. This type of modifi-
cation affects frequently protein-protein interactions, protein-
DNA interactions or protein degradation (due to competition 
with the ubiquitination machinery for the same lysine) [12, 
13].  
  The function of certain proteins can further be influenced 
by covalent addition of members of the family of small 
ubiquitin-like proteins. The first protein of this group that 
was identified was ubiquitin itself, a protein of 76-amino 
acids that is ubiquitously expressed from yeast to man [re-
viewed in: 14]. Ubiquitin is implicated in a multitude of cel-
lular processes like regulation of the cell cycle, DNA replica-
tion, DNA repair, stress response, apoptosis, signal transduc-
tion or in the biogenesis of ribosomes, nucleosomes and per-
oxisomes [reviewed in: 15-17]. The covalent ligation of 
ubiquitin is an extremely conserved process and involves 
several enzymes and accessory proteins that are generally 
highly conserved across different species [reviewed in: 15]. 
Moreover, the attachment of ubiquitin onto a target protein 
ranges from the attachment of only one ubiquitin molecule to 
one lysine (monoubiquitination) over the addition of one 
ubiquitin to several lysine residues within the same protein 
(multiubiquitination) to the formation of chains of ubiquitin 
molecules on one individual lysine (polyubiquitination) [re-
viewed in: 18]. Since the ubiquitin protein itself possesses 7 
lysine residues (lysine 6, lysine 11, lysine 29, lysine 31, ly-
sine 33, lysine 48, lysine 63), which all can serve as an an-
chor for ubiquitination, a variety of chains can be formed 
that control different properties [reviewed in: 19, 20]. Polyu-
biquitination of lysine 48 is the prototype for chains that lead 
to proteosomal degradation, although more recent reports 
showed that polyubiquitination of lysine 11 and eventually 
also of lysine 63 can target substrate proteins for destruction 
[21, reviewed in: 19, 20]. Proteins that are polyubiquitinated 
at lysine 63 are frequently implicated in DNA repair, while 
chain formation at lysine 29 seems to label their targets for 
lysosomal degradation [22, 23]. In addition, polyubiquitin 
chains are not necessarily homotypic. Chains, containing two 
types of linkages (lysine 6/11, lysine 27/29, lysine 29/48; 
lysine 29/33) have also been observed [24]. Like phosphory-
lation or acetylation, the modification of proteins with ubiq-
uitin is reversible. Specific deubiquitinating enzymes 
(DUBs) hydrolyze the isopeptide bond between ubiquitin 
and its substrate and thus remove the ubiquitin molecule or 
chain from its target [reviewed in: 25].  
  Another member of the ubiquitin family is SUMO (small 
ubiquitin-like modifier), a small polypeptide of 10-11 kDa 
[reviewed in: 26, 27]. SUMOylation is frequently involved 
in the control of recombination, DNA repair, nucleo-
cytoplasmatic transport, chromosomal dynamics, meiosis 
and mitosis and the maintenance of genomic stability [re-
viewed in: 26, 27]. In addition, it can protect proteins from 
proteasomal degradation, most likely through rivalry with 
the ubiquitination machinery for the same lysine residue 
[27]. The process of SUMOylation is mechanistically related 
to ubiquitination, as an enzyme cascade consisting of a 
SUMO-activating enzyme (E1), a SUMO-conjugating en-
zyme (E2) and a SUMO-ligase (E3) controls the process of 
SUMOylation of target proteins. Until today several SUMO-
ligases have been identified including PIASx, PIASx, 
PIAS1, PIAS3, PIASy, RanBP2 (Ran-binding protein 2), 
Pc2 and HDAC4 (histone deacetylase 4) [reviewed in: 26, 
27]. In contrast to ubiquitination, a SUMO-ligase is not 
obligatory for SUMOylation but some mammalian SUMO-
specific E3s stimulate the conjugation reaction, eventually 
even in a substrate independent manner [28]. The vast major-
ity of SUMO substrates are directly recognized by the 
SUMO-conjugating enzyme, Ubc9, that binds to the consen-
sus sequence KxE/D (where  is a large hydrophobic 
amino acid) [29, 30]. However, polymers of both, SUMO-1 
and SUMO-2/3, have also been found at lysines that do not 
comply with the consensus motif [31, 32]. Since the SUMO-
conjugating system utilizes only a single enzyme for the rec-
ognition and conjugation processes, a further level of regula-
tion must be provided. This is frequently given by an exten-
sion of the recognition motif that may contain phosphory-
lated (PDSM; phosphorylation-dependent SUMOylation 
motif) or negatively charged (NDSM; negatively charged 
amino acid-dependent SUMOylation motif) amino acids in 
addition to the KxE/D motif [33, 34]. Phosphorylation 
within the PDSM consensus sequence plays an important 
role in regulating SUMOylation of several substrates includ-
ing p53, heat shock factors, GATA-1 and the myocyte en-
hancer factor-2 (MEF2A) [33-35]. Today, four isoforms of 
SUMO (SUMO-1 to SUMO-4) have been identified in 
mammals and transcripts of SUMO-1, -2 and -3 can be de-
tected in all human and mouse tissues, whereas SUMO-4 
expression seems to be restricted to immune tissues and to 
the kidney [36, 37]. SUMO-4 was initially identified as an 
intronless gene, encoding a protein that shares 86% amino 
acid homology with SUMO-2 [38]. SUMO-4 seems to be 
unable to form covalent isopeptide bonds with substrate pro-
teins and may control protein functions via  non-covalent 
interactions [39]. SUMO-2 and SUMO-3 are conjugated in a 
stress inducible manner [reviewed in: 26]. They are very 
similar on the amino acid level but share only 47% identity 
to SUMO-1. In contrast to ubiquitin, SUMOylation usually 
conjugates only a single SUMO molecule to a substrate. 
Nevertheless, recent reports also implicated the formation of 
SUMO-chains [31, 40]. Like ubiquitination, SUMOylation 
can be reversed. SUMO-hydrolyses of the SENP family 
(sentrin- or SUMO-specific protease) remove SUMO mole-
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  The 81 amino acid polypeptide NEDD8 (neural-
precursor-cell-expressed developmentally down-regulated 8) 
is a relatively uncharacterized member of the family of ubiq-
uitin-like proteins [reviewed in: 41]. Nevertheless, genetic 
approaches have exposed an obvious role for NEDD8 in cell 
proliferation, viability and development although the number 
of known substrates is rather small. Like ubiquitination and 
SUMOylation, the conjugation of NEDD8 to its substrate is 
initiated by an activating enzyme, followed by the activity of 
an E2 enzyme and an E3 ligase [reviewed in: 41]. In line 
with the other modifications, the process of NEDDylation is 
very dynamic and NEDD8 can be removed e.g. by the evolu-
tionarily conserved COP9 signalosome [reviewed in: 42].  
DNA DAMAGE RECOGNITION AND INITIAL SIG-
NALLING EVENTS 
  Once a DSB is generated, the information about this 
damage needs to be propagated to downstream effector ma-
chineries such as repair proteins, cell cycle checkpoints and 
cell death pathways. Accordingly, recognition of the lesion is 
the first and initial step in the DNA damage response. In a 
second step, the information about the lesion can then be 
transported across the damaged cell. Each specific lesion of 
the DNA is recognized by one or a set of individual DNA 
damage recognition factors that are associated with certain 
signaling components. Double strand breaks are generally 
recognized by the ataxia-telangiectasia-mutated (ATM) and 
by the DNA-damage-dependent protein kinase (DNA-PK).  
  ATM is a serine/threonine protein kinase with a multi-
tude of activities. It signals the presence of DSBs to the cell 
cycle machinery where it mediates proliferation arrest at 
G1/S, intra-S and G2/M checkpoints (Fig. 1). The kinase is 
furthermore required for DNA repair and contributes to the 
initiation of apoptosis (Fig. 1) [reviewed in: 43]. Mutations 
in the ATM gene lead to the genetic disorder ataxia-
telangiectasia (AT), which is characterized by cerebellar 
degeneration, immunodeficiency and an increased risk of 
cancer. Cells from AT patients are hypersensitive to ionizing 
radiation and display an increased frequency of chromosome 
breakage and defects in cell cycle control [reviewed in: 43]. 
ATM is primarily a nuclear protein where it is present as an 
inactive dimer or multimer (Fig. 2). The kinase is, further-
more, associated with protein phosphatase 2A (PP2A), a 
serine/threonine phosphatase that associates with ATM via 
its scaffolding A-subunit [44]. PP2A dephosphorylates ATM 
constitutively, which keeps the kinase in an inactive state 
[44]. In addition to PP2A, ATM was found associated with 
protein phosphatase 5 (PP5). This interaction of ATM with 
PP5 increases after exposure of cells to DNA damaging 
agents and appears to be important for ATM activity in re-
sponse to DSBs [45]. How ATM becomes activated in the 
presence of DSBs is not entirely solved. A previous model 
suggested that upon sensing of a DSB, ATM becomes par-
tially active, resulting in trans-autophosphorylation of ATM 
at serine 367, serine 1893 and serine 1981, and dissociation 
of ATM dimers/multimers into highly mobile and enzymati-
cally active monomers that associate with damaged chroma-
tin [46, 47]. More recently, this model of ATM activation 
has been questioned. Jean Gautier and co-workers showed 
that the MRN complex and DNA are sufficient to facilitate 
ATM monomerisation [48]. In addition, phosphorylation of 
serine 1981 appears to be optional for the dissociation of 
ATM or its function in general [49]. ATM even remained 
functional when additional autophosphorylation sites (serine 
367 and/or serine 1893) were mutated [50]. Besides phos-
phorylation, ATM also becomes acetylated in response to 
DSBs. Tip60 (HIV-1 Tat-interacting protein 60 kDa) acety-
lates ATM on lysine 3016 and this modification is essential 
for ATM activation and dissociation into monomers [51]. It 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). ATM and its target proteins. In the active state ATM phosphorylates target proteins that signal to cell cycle checkpoints, DNA 
repair proteins or to the cell death machinery. Phosphorylation of Brca1 or the activation of the MRN complex results in the initiation of 
DNA repair. Activation of cell cycle checkpoints that lead to cell cycle arrest are achieved by phosphorylation of the p53 tumor suppressor 
protein or the Chk2 kinase. In addition, by transcriptional induction of pro-apoptotic proteins like Bax and PUMA, p53 can also induce apop-
tosis. Regulation of the DNA Damage Response  Current Genomics, 2010, Vol. 11, No. 3    187 
is, though, unclear by which mechanism Tip60 becomes ac-
tivated in the presence of DSBs. Also Aven, an interaction 
partner of the anti-apoptotic protein Bcl-XL, has been re-
ported to contribute to ATM activation [52]. Aven interacts 
with ATM in cellular extracts and overexpression of Aven 
promotes ATM phosphorylation on serine 1981 as well as 
phosphorylation of typical ATM substrates like p53 and 
Chk2 [52]. However, since Aven is less efficient than DSB 
in inducing ATM autophosphorylation it appears to act syn-
ergistically with DNA damage rather than being a sole acti-
vator of the kinase. 
  Apart from ATM is DNA-PK (DNA-dependent protein 
kinase) able to recognize DSBs [53]. Like ATM, DNA-PK 
has a strong affinity to DNA. Its recruitment to sites of DNA 
damage is conducted by a heterodimer of the Ku70 and 
Ku80 proteins [54]. The Ku70/80 heterodimer forms a ring-
shaped structure that can be threaded onto DNA ends [54]. 
Due to its high affinity for loose DNA ends and its capacity 
to bind DNA in a sequence-independent fashion, the 
Ku70/80 heterodimer is believed to serve as a DSB sensor. 
Once the Ku70/80 heterodimer is bound to damaged DNA, it 
serves as a docking site for the catalytic subunit of the DNA-
dependent protein kinase (DNA-PKcs), which results in the 
formation of the DNA-PK holocomplex that displays ser-
ine/threonine kinase activity towards p53, H2AX, Artemis, 
XLF and others [55-58]. Formation of the heterodimeric 
holocomplex is mediated by the amino-terminal and the cen-
tral region of both, the Ku70 and Ku80 protein. The Ku80 
carboxy-terminus is, furthermore, required for DNA-PKcs 
autophosphorylation at threonine 2609 [59]. This phosphory-
lated form of DNA-PK co-localizes with -H2AX and 
53PB1 at the DSB [59].  
  After recognition of the lesion, an operation platform for 
repair factors needs to be generated. Since eukaryotic DNA 
is organized in tightly packed nucleosomes, these structures 
need to be widened to allow recruitment of repair proteins 
and to enable their interaction with damaged DNA. For this 
purpose, different residues of certain histone proteins be-
come post-translationally modified. Especially acetylation, 
methylation, phosphorylation and ubiquitination of histone 
proteins have been observed during the DNA damage re-
sponse [60-65]. The main purpose of acetylation and phos-
phorylation seems to be to neutralize the positive charge of 
basic histone proteins. This would reduce the strength of the 
interaction of basic histone proteins with negatively charged 
DNA and may decondensate the chromatin. The earliest 
post-translational modification event at the chromatin as well 
as for the initiation of the DNA repair process is phosphory-
lation of the histone H2A variant H2AX at serine 139. The 
modified H2AX protein, which is called -H2AX, appears 
within a few minutes after exposure of cells to ionizing ra-
diation at the break [64]. Beside H2AX is histone H3 post-
translationally modified after a DSB. Within a few minutes 
after introduction of a DSB, H3 becomes methylated at ly-
sine 79 [66]. Both histone modifications are required for 
recruitment of mediator proteins such as 53BP1 (p53-
binding protein1), MDC1 (mediator of DNA damage check-
point protein 1) or the MRN (Mre11, Rad50, Nbs1) complex 
to the DSB [66-69] (Fig. 3).  
  The MRN complex, a highly conserved protein complex 
consisting of Mre11, Rad50 and Nbs1 (Nijmegen breakage 
syndrome 1), is implicated in DNA repair, cell cycle check-
point control, DNA replication and telomere maintenance 
[70-72]. The three proteins, Mre11, Rad50 and Nbs1, form a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). ATM activation and downstream signaling. (A) ATM is present in the nucleus as an inactive dimer/multimer that is associated 
with PP2A, a phosphatase that controls ATM phosphorylation. Upon ionizing radiation (IR), ATM is activated by trans-autophosphorylation 
and dissociation of the dimer/multimer into monomers as well as by Tip60-mediated acetylation, which enables ATM-mediated phosphoryla-
tion of mediator and DNA repair proteins. 188    Current Genomics, 2010, Vol. 11, No. 3  Oberle and Blattner 
tight complex which is homogenously distributed throughout 
the nuclei of mammalian cells but migrates rapidly to DSBs 
after ionizing radiation, independent of the phase of the cell 
cycle [73]. The Nbs1 protein appears to be responsible for 
nuclear localization and the proper assembly of the complex 
at DSB sites, probably by interacting with phosphorylated 
H2AX [68]. Mre11 displays endo- and exonuclease activity 
and is important for the processing of the broken DNA ends 
[74]. Rad50 also shows DNA binding capacity that possibly 
plays a role in tethering sister chromatids during HR [75, 
76]. The MRN complex is composed of a single Nbs1 mole-
cule that is associated with two dimers of Mre11 and Rad50. 
The Mre11 and Rad50 proteins themselves form a hetero-
tetramer consisting of a dimer of Mre11 and Rad50. This 
heterotetramer contains two DNA-binding and processing 
domains that can bridge free DNA ends [76, 77]. The Mre11 
dimer binds and holds the dsDNA ends in close proximity, 
near the Mre11 active site and it is thought that it aligns and 
bridges these loose DNA ends during DNA repair [78, 79]. 
Rad50 contains two long coiled-coil arms that promote in-
termolecular interactions through a terminal hook domain 
[76, 77]. Loss of Nbs1 or Mre11 is embryonic lethal [80, 81] 
and mutations in NBS1 and MRE11 lead to the chromoso-
mal instability disorders Njimegen breakage syndrome (mu-
tation in NBS) and ataxia telangiectasia-like disorder 
(ATLD; mutation in Mre11). Both of these syndromes are 
associated with enhanced sensitivity to ionizing radiation 
and chromosomal instability [reviewed in: 82, 83]. MRN 
binds to DSBs and leads to further activation of ATM [48, 
70]. Accordingly, cells derived from patients with Nijmegen 
breakage syndrome or ataxia telangiectasia-like disorders 
exhibit decreased ATM kinase activity despite the presence 
of wild type ATM [70, 84-86]. The nuclease activity of 
Mre11 appears to be particularly important for this process 
[70, 87]. Despite the similar timing of the appearance of 
Ku70/80 and the MRN complex at DSBs, recruitment of 
MRN and Ku seems to be independent of each other [88]. 
Nbs1 and Mre11 are both targets for ATM and at least phos-
phorylation of Nbs1 is required for checkpoint signaling dur-
ing S-phase [89]. Therefore the MRN complex acts on the 
one hand as a downstream mediator of ATM but is also 
important for the activation of ATM and phosphorylation of 
downstream substrates.  
  MDC1, also called NFBD1 (nuclear factor with BRCT 
domains protein 1), appears to be a master regulator of the 
microenvironment at damaged chromatin. The docking of 
MDC1 to DSBs allows retention of multiple checkpoint and 
adaptor proteins including Nbs1, 53BP1 or Brca1 (breast 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). DNA lesion recognition and recruitment of repair factors. After introduction of a DNA double strand break (I), the DNA dam-
age response is initiated by phosphorylation of H2AX (II), which is required for the recruitment of mediator proteins such as MDC1 or the 
MRN complex. MDC1 attaches to phosphorylated H2AX via its BRCT domain and stabilizes the MRN complex (III). Additionally it is 
responsible for binding and accumulation of ATM at the DSB, which creates a docking site for RNF8/Ubc13 that also associates with phos-
phorylated H2AX and decorates histone proteins with lysine 63-linked ubiquitin molecules (IV). RNF168 recognizes the initial ubiquitin 
chains generated by RNF8 and, in association with Ubc13, extends and propagates lysine 63-linked ubiquitination (V) that is required for the 
accumulation of additional repair factors like Bcra1 or 53BP1 (VI).  Regulation of the DNA Damage Response  Current Genomics, 2010, Vol. 11, No. 3    189 
cancer 1) at the site of the lesion where they provide a mo-
lecular platform for efficient amplification of the DNA dam-
age signal [68, 69, 90]. For this, MDC possesses two classes 
of phospho-binding motifs, a FHA (forkhead-associated) and 
a BRCT (Brca1 carboxy-terminal repeat) domain that serve 
as binding partners for phosphorylated proteins. BRCT and 
FHA modules are conserved throughout different species 
and are present in many proteins that are involved in the cel-
lular response to DNA damage [reviewed in: 91, 92]. Two 
repeats of the BRCT domain are located at the carboxy-
terminus of MDC1. These BRCT domains associate directly 
with phosphorylated H2AX and this interaction seems to be 
essential for the recruitment and docking of MDC1 to the 
site of the DNA lesion (Fig. 3). Accordingly, in H2AX
-/- 
MEFs, MDC1 fails to accumulate at DSBs [90]. The FHA 
domain is positioned at the amino-terminus and binds to 
ATM which results in the accumulation of ATM at DSBs 
and enhanced phosphorylation of H2AX and of MDC1 itself 
[93]. In MDC1-deficient cells, recruitment of ATM to DSBs 
is impaired [93]. The central domain of MDC1 contains 14 
repeats of a sequence that mediate its interaction with DNA-
PKcs and the Ku heterodimer [94]. Once recruited to DSBs, 
MDC1 stabilizes the MRN complex that is bound to dam-
aged DNA and acts as a molecular scaffold for the recruit-
ment of 53BP1, BRCA1 and additional MRN molecules to 
nuclear foci [68, 90, 95]. Upon binding to MDC1, ATM 
phosphorylates the mediator protein and this phosphorylation 
creates a docking site for the recently identified E3-ligase 
RNF8 (ring finger 8) and for Ubc13 (ubiquitin-conjugating 
13; Fig. 3) [22, 96]. These proteins associate with -H2AX 
and phosphorylated MDC1 via their FHA domains and deco-
rate the histone protein H2A and its variant H2AX with ly-
sine 63-linked polyubiquitin chains [22, 96]. Nevertheless, 
although RNF8 seems to be the first E3 ligase at the DSB, it 
appears to be insufficient for sustained ubiquitination of the 
chromatin. It probably rather primes the chromatin around 
the DSB, which then facilitates the recruitment of another E3 
ligase, the RNF168 protein (Fig. 3) [97]. RNF168 recognizes 
the initial ubiquitin chains generated by RNF8 via its ubiq-
uitin-binding domain and, in concert with Ubc13, propagates 
and extends the formation of lysine 63-linked ubiquitin 
chains of histone proteins. Eventually, a threshold of lysine 
63-polyubiquitin chains may be required to recruit and hold 
additional repair factors at the DSB. Particularly recruitment 
of 53BP1 and Brca1 are assumed to depend on such an “in-
teraction trap” made of polyubiquitinated lysine 63 chains 
(Fig.  3) [97]. After polyubiquitination of the chromatin, 
Brca1, a tumor suppressor protein that also possesses ubiq-
uitin ligase activity, especially when it is complexed with 
Bard1, is recruited to the lesion together with Rap80, 
Abraxas, Brca1 and Brcc36, which form the BRCA1-A 
complex [98]. Brca1 can be found in three different com-
plexes (Brca1 A, B and C), which depend on different adap-
tor proteins. The adaptor proteins for the complex A, B and 
C are Abraxas, Bach1/Brip1 (BRCA1-associated C-terminal 
helicase) and CtIP (CtBP-interacting protein), respectively. 
Each complex forms in a mutually exclusive manner [98-
100]. Whereas complex A plays an important role in DNA 
damage repair, the Brca1/Bach1 and the Brca1/CtIP complex 
form at different stages of the cell cycle and are required for 
a prolonged G2 phase and for G2/M transition checkpoint 
control, respectively [99, 100]. Ionizing radiation leads to 
ATM-dependent phosphorylation of Rap80 (receptor-
associated protein 80) at serine 140, serine 402 and serine 
419 [22, 98]. RAP80, furthermore, possesses two ubiquitin 
interaction motifs (UIM) which recognize lysine 63-linked 
ubiquitin chains. These UIMs facilitate the association of the 
complexes with polyubiquitinated histone proteins [22, 97]. 
Brcc36 of the complex has ubiquitin hydrolyzing activity 
and plays an important role in the regulation of the E3 ligase 
activity of  Brca1 in response to ionizing radiation [101, 
102]. The Rap80/Brcc36 complex furthermore removes ly-
sine 63-linked polyubiquitin chains from the chromatin and 
is thus also involved in the termination of RNF8-Ubc13-
mediated polyubiquitination once the lesion has been re-
paired [103]. Although primarily implicated in HR, there is 
accumulating evidence that Brca1 may also be involved in 
NHEJ. The N-terminal region of Brca1 specifically associ-
ates with Ku80 and rapidly accumulates at DSBs in a Ku-
dependent manner. Brca1 is furthermore assumed to control 
the fidelity of NHEJ [104, 105]. 
  53BP1 functions, together with MDC1 and Brca1, as an 
adaptor/mediator protein of the DNA damage response. As 
such, it contributes to the activation of downstream effector 
molecules that function in DNA repair and DNA damage 
signaling, although it has no enzymatic activity. 53BP1 was 
originally identified due to its ability to bind to p53 [106]. 
Upon ionizing radiation, it accumulates in foci at DSBs and 
becomes phosphorylated at several sites in an ATM-
dependent manner. Among these is phosphorylation of serine 
1219 particularly important as phosphorylation of this site 
assists in recruitment of MDC1 and -H2AX [107]. 53BP1 is 
furthermore required for p53 accumulation, G2/M and intra-
S-phase arrest, ATM autophosphorylation at serine 1981 and 
for the formation of Brca1-containing foci in response to 
ionizing radiation [108, 109].  
DOUBLE STRAND BREAK REPAIR AND SIGNAL 
TRANSDUCTION 
  After the generation of a protein interaction platform, 
repair factors are recruited to the DSB that ligate the broken 
DNA ends. In mammalian cells DSBs are usually repaired 
by non-homologous endjoining (NHEJ) and homologous 
recombination (HR) (Fig. 4). In dependence on the phase of 
the cell cycle the one or the other mechanism dominates. 
Nevertheless, while it was previously suggested that during 
the G1 and early S phase of the cell cycle, NHEJ is the 
pathway of choice and HR would only be operative in late S 
and G2, it becomes more and more evident that at least 
NHEJ is active in all phases of the cell cycle [110, 111]. This 
is, for example, evidenced by the appearance of Ku70/80, 
DNA-PKcs and ATP-dependent DNA ligase IV (LigIV) at 
DSBs not only in G1 but also in S and G2 phase. Neverthe-
less, although proteins of both repair pathways appear at the 
same DSB, assembly of the NHEJ machinery clearly pre-
cedes that of HR factors, even in the S and G2 phase of the 
cell cycle [88, 112, 113]. Moreover, the fact that factors of 
both repair machineries are present at DSBs at the same time 
suggests that NHEJ and HR are not two competing parallel 
pathways but rather that NHEJ may serve as an immediate 
early repair event whereas HR may repair persisting DNA 
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Non-Homologous Endjoining (NHEJ) 
  NHEJ is the repair pathway of choice of non-dividing 
and of mitotic cells during G1 and early S-phase of the cell 
cycle. Since most cells of higher organisms are in a quies-
cent state, NHEJ is considered to be the major DSB repair 
pathway in mammals. The process of NHEJ is characterized 
by a “simple” ligation of broken ends without the require-
ment for larger sequence homologies. However, since the 
creation of ligatable DNA ends usually comes along with 
loss of genetic information, it is also an error-prone DNA 
repair mechanism.  
  The mechanism of NHEJ covers mainly four consecutive 
phases (i) recognition of the DNA lesion, (ii) sequential re-
cruitment of repair factors, (iii) processing of DNA ends to 
yield ligatable termini and (iv) sealing of the break. To date 
seven proteins have been described to be required for NHEJ: 
the Ku70/Ku80 heterodimeric complex, DNA-PKcs, LigIV, 
XRCC4 (X-ray repair complementing group 4 protein), XLF 
(XRCC4-like factor) and Artemis (Fig. 4) [114-121]. If a cell 
is defective in one of these enzymes, neither DNA repair nor 
V(D)J recombination, a cut-and-paste mechanism that uses 
NHEJ to seal DSBs that arise during the generating of the 
diversity of antigen receptors in immune cells [reviewed in: 
122], can be carried out. This results in enhanced sensitivity 
towards ionizing radiation and in immunodeficiency [114, 
116, 120, 121, 123].  
  The Ku70/80 heterodimer serves as a recognition and 
first docking molecule at DSBs and it most likely also pro-
tects DNA ends from nucleolytic degradation (Fig. 4) [114, 
124, 125]. In vivo studies with Ku-deficient yeast strains 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Mechanisms of DNA-repair by NHEJ and HR. Double strand breaks are repaired by two major pathways: non-homologous  
endjoining (A, NHEJ) and homologous recombination (B, HR). NHEJ: Loose DNA-ends are recognized by the Ku70/80 heterodimeric 
complex (A.I), which is needed for the recruitment of the additional repair factors DNA-PKcs, XRCC4, LigIV and XLF (A.II). Before bro-
ken DNA ends can be ligated, the ends are processed by Pol  and , Artemis and Tdt (A.III). This step is followed by the ligation of the 
loose ends by LigIV and XRCC4 (A.IV). HR: HR is initiated by the MRN complex (B.I), followed by the recruitment of RPA that associ-
ates with single stranded DNA, and by Rad51/52 which are needed for filament formation and strand invasion (B.II). New DNA is synthe-
sized while the homologous sister chromatid serves as a template (B.III). After branch migration, the holiday junction is resolved (B.IV). Regulation of the DNA Damage Response  Current Genomics, 2010, Vol. 11, No. 3    191 
demonstrated that Ku is important for efficient NHEJ and for 
accurate rejoining of complementary and non-
complementary DNA ends [114]. The recruitment of 
Ku70/80 is followed by the arrival of DNA-PKcs at the DSB 
and its autophosphorylation (Fig. 4). Mutation of the auto-
phosphorylation site of DNA-PKcs impairs rejoining of bro-
ken DNA [59]. After the arrival of DNA-PK, the DNA at the 
break is processed. DSBs frequently lead to damaged bases 
or incompatible single strand overhangs at the break, which 
are unsuitable for direct ligation. Several enzymes with sin-
gle-strand filling capacity or nucleolytic trimming potency 
have been suggested to play a role in the processing of the 
DNA, like polymerase , polymerase μ, Tdt (terminal de-
oxynucleotidyltransferase) and Artemis (Fig. 4). These en-
zymes add or remove nucleotides or extend the 3´-single 
stranded DNA tail in a template-independent manner. The 
DNA polymerases  and μ are responsible for refilling the 
gaps that result from NHEJ intermediates while Tdt adds 
nucleotides to loose ends during V(D)J recombination [126-
128]. Artemis, on the other hand, displays an intrinsic 5´-
3´exonuclease activity in vitro and assists in the repair of a 
subset of DSBs [129]. Upon forming a complex with DNA-
PKcs, Artemis becomes phosphorylated, which facilitates 
cleavage of 5´and 3´overhangs, nicks and hairpin structures 
at the loose end of the DNA [129]. Artemis is furthermore 
important for the opening of hairpin structures during V(D)J 
recombination [129].  
  LigIV is a core component of the NHEJ repair pathway 
and catalyzes the ligation of the DNA ends (Fig. 4). Struc-
tural studies have revealed that LigIV exists in a tight com-
plex with XRCC4 that is accomplished by the central region 
of XRCC4 and that strongly enhances LigIV stability [117, 
130, 131]. XRCC4 is a nuclear protein that is constitutively 
phosphorylated and its phosphorylation is further enhanced 
in response to ionizing radiation in a DNA-PK-dependent 
manner [132]. In addition to phosphorylation, a monoubiq-
uitinated form of XRCC4 has been identified. The abun-
dance of this modified form is enhanced when cells have 
been treated with etoposide, a topoisomerase inhibitor that 
generates DSBs [133]. The precise role of this ubiquitination 
of XRCC4 has, though, not been determined. In addition to 
phosphorylation and ubiquitination, XRCC4 is modified 
with SUMO at lysine 210, a modification that appears to be 
required for nuclear localization of the protein [134].  
  More recently XLF (XRCC4-like factor), also called 
Cernunnos, was identified as a new interaction partner of 
XRCC4 and an additional member of the NHEJ machinery 
[118, 119]. XLF forms homodimers with a XRCC4-like 
structure and modulates XRCC4/LigIV activity through di-
rect interaction with XRCC4 [135, 136]. XLF is quickly re-
cruited to DSBs in a Ku-dependent and XRCC4-independent 
manner [137]. Although XLF is phosphorylated by DNA-PK 
at serine 245 and by ATM at serine 251, no particular func-
tion could be attributed to these modifications [58].  
  Once repair is completed, the repair machinery needs to 
be disassembled, but how this is achieved has not yet been 
understood in detail. Only for the Ku70/80 proteins some 
insights into this process have been  provided. Recently it 
was demonstrated that Ku80 bound to DSB is heavily modi-
fied with polyubiquitin chains. This modification appears to 
mediate efficient removal of Ku80 from repaired DNA 
[138]. Most interestingly, binding of Ku to DNA appears to 
initiate its polyubiquitination, which then allows its removal 
from the DNA once the lesion is fixed [138]. 
 While the classical NHEJ pathway uses the 
XRCC4/LigIV complex to ligate broken DNA ends, the im-
mune system can make use of an alternative NHEJ pathway 
that is XRCC4-independent  [139]. This alternative NHEJ 
mechanism deletes sequences at the loose ends until short 
stretches of homology appear at the repair junction. These 
areas of microhomology assist in ligation in a process called 
microhomology-mediated endjoining (MMEJ). It is most 
likely that the enzymatic and scaffolding function of Mre11 
participates in this process [140]. Whether this alternative 
route of NHEJ also contributes to the sealing of DSBs after 
ionizing radiation, e.g. when XRCC4 is absent, remains to be 
determined.  
Homologous Recombination (HR) 
  HR is particularly activated during late S- and G2-phases 
of the cell cycle as this repair pathway requires sequence 
homologies of about 100 base pairs and more in close prox-
imity to the damaged site. These conditions are normally 
only provided between DNA replication and cell division. 
Since the undamaged sister chromatid is used as a template, 
this type of repair is generally accurate. As HR requires the 
alignment of broken DNA ends with a homologous region of 
the genome, homology search and DNA strand invasion is a 
central component of HR. After introduction of a DSB, HR 
is generally initiated by nucleolytic resection of the broken 
DNA which results in long single stranded tails with 3´-
hydroxyl overhangs. It is most likely that the Rad50/Mre11 
complex contributes to this activity [78]. The resulting single 
stranded DNA (ssDNA) is bound by the replication protein 
A (RPA) (Fig. 4) [141]. RPA is a heterotrimeric, eukaryotic 
protein that binds to ssDNA in a sequence independent man-
ner thus forming a nucleoprotein filament [reviewed in: 
142]. Apart from protecting the ssDNA from nucleolytic 
attacks, RPA eliminates secondary structures, which allows 
more Rad51 molecules to access and bind ssDNA, thus 
stimulating the formation of a presynaptic complex of DNA, 
RPA and Rad51. RPA can have positive and negative effects 
on Rad51-mediated strand exchange. Pre-incubation of 
ssDNA with RPA protein prevents binding of Rad51 to the 
DNA but this inhibitory effect can be diminished by Rad52 
or Rad55/57. The Rad55/57 complex interacts transiently 
with Rad51 which results in the abolishment of the RPA 
inhibitory effect and support of the formation of the Rad51 
filament, similar to Rad52 [143]. In contrast, when RPA is 
present after the Rad51/DNA complex has formed, it is able 
to stimulate strand exchange via Rad51, possibly by remov-
ing secondary structures of the ssDNA, and to promote ap-
propriate Rad51 filament formation [141, 144].  
  The main activity of Rad51 is to promote ATP-dependent 
strand exchange, catalyzed by an intrinsic ssDNA-dependent 
ATPase activity [141, 145]. Accordingly, yeast cells lacking 
Rad51 are hypersensitive to ionizing radiation and alkylating 
agents [141, 146]. In humans, five Rad51 paralogs exist 
named Rad51B, Rad51C, Rad51D, XRCC2  and XRCC3 
[reviewed in: 147]. The mammalian counterpart of Rad52 is 
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cancer. Similar to the yeast counterpart, Brca2 controls the 
activity of the recombinase, Rad51, and stimulates the load-
ing of Rad51 onto ssDNA [148-150]. Once Rad51 has been 
recruited to the nucleoproteinfilament, it replaces RPA. The 
3´-overhangs of the DNA associate with Rad52 and subse-
quently with polymerized Rad51 and form the so-called 
recombinase filament where Rad51 and Rad52 are wrapped 
around the ssDNA overhang. This interaction is stabilized by 
Rad54 that associates with the recombinase filament and 
enhances their catalytic activity [151]. Once this complex is 
complete, the tail of Rad52 starts to search for a homologous 
sequence in the sister chromatid and facilitates base pairing 
with the single-stranded overhang to form a D-loop interme-
diate. This homology search is furthermore assisted by 
Rad51 which, together with the ssDNA, invades into the 
intact homologous chromosome to form a heteroduplex. 
Rad54 appears to help in this process, although its precise 
function remains to be determined [152]. After formation of 
the heteroduplex, DNA polymerase  and  extend the 3´end 
of the invading strand in a process called branch migration 
(Fig. 4) [153]. Due to strand invasion, a joint molecule with 
crossed-over DNA strands is generated. To finish the repair 
process, these holiday junctions need to be resolved in order 
to reconstruct the two individual DNA double helices. The 
resolution of the holiday junction is performed by the resol-
vases Rad51C and XRCC3 (Fig. 4) [153-156]. 
CELL CYCLE ARREST AND APOPTOSIS 
  In mammalian cells, evolutionary conserved pathways 
exist that signal information about the state of the genome to 
a series of checkpoints, which can delay the progression into 
the next phase of the cell cycle. All these checkpoints are 
tightly regulated. In response to DNA damage, errors in 
DNA replication or chromosome segregation, cells can acti-
vate these checkpoints to allow time to fix the lesion before 
the cell reinitiates replicative DNA synthesis or begins mito-
sis. The most important checkpoints within the cellular re-
sponse to DNA damage are the G1/S and the G2/M check-
points. In addition, an intra-S-phase checkpoint exists [re-
viewed in: 157]. 
  After sensing of the DSB, the information about the le-
sion is rapidly transduced to the checkpoints of the cell cy-
cle. ATM and Chk2 (cell cycle checkpoint kinase 2) kinases 
play an important role in this process [158-160]. Chk2 is a 
stable protein which is expressed throughout the cell cycle. 
In the absence of DNA damage Chk2 is largely inactive. 
When DNA damage occurs, the kinase becomes rapidly 
phosphorylated at threonine 68 by ATM [158]. This phos-
phorylation stimulates Chk2 homodimerisation and activates 
the kinase, which results in autophosphorylation at threonine 
383, threonine 387 and serine 516, and phosphorylation of 
Chk2 target proteins [159-161]. One of the targets of Chk2 is 
Cdc25A, a phosphatase that dephosphorylates and activates 
cyclin-dependent kinases (Cdks) (Fig. 1) [162]. These 
kinases drive the cell trough the cell cycle. Phosphorylation 
of Cdc25 by Chk2 in response to DSBs leads to rapid pro-
teosomal degradation of the phosphatase and thus to inacti-
vation of cdk2/cyclin E/A complexes as well as of 
cdk2/cyclin B/A complexes, which result in cell cycle arrest 
at the G1/S and G2M checkpoint, respectively [162, 163].  
  An additional important component of checkpoint activa-
tion in response to DNA damage is the p53 tumor suppressor 
protein (Fig. 1). Most characteristic for p53 are its prolifera-
tion-inhibiting and pro-apoptotic activities. Many, but not all 
of these activities are caused by its function as a transcription 
factor. Under normal growth conditions, the amount of the 
p53 protein is maintained low and the protein is transcrip-
tionally inactive. Both parameters are mainly controlled by 
the E3 ubiquitin ligase Mdm2, although other proteins may 
also contribute to this process [reviewed in: Boehme and 
Blattner, in press]. Mdm2 binds to the N-terminal transacti-
vation domain of p53 and mediates its ubiquitination and 
proteosomal degradation [164]. Upon DNA damage, p53 is 
protected from degradation and post-translationally modified 
at several sites in its amino- and carboxy-terminal part, 
which enhances its sequence-specific binding to promoters 
of target genes and activation of gene transcription [12, 165-
168]. Among the target genes of p53 are bax, puma and p21, 
while transcription of other genes, such as bcl-2 are re-
pressed [169-171, reviewed in: 172]. p21, also known as 
p21
WAF1/Cip1 is a member of the Cip/Kip family of cyclin-
dependent kinase inhibitors [reviewed in: 173]. Cyclin de-
pendent kinases 2, 4 and 6 (Cdk2, Cdk4, Cdk6) and the asso-
ciated cyclins, control progression through the cell cycle by 
phosphorylation of their target proteins [174]. An important 
substrate of theses cyclin/Cdk complexes is the retinoblas-
toma protein (Rb), a transcriptional repressor of the E2F 
family of transcription factors. E2F proteins control entry 
into and progression through the S-phase of the cell cycle. In 
its hyperphosphorylated state, Rb binds to E2F family mem-
bers and prevents them from activating their target genes, 
which, at the same time, precludes entry into the S-phase of 
the cell cycle [175, 176]. In unstressed cells, Rb becomes 
phosphorylated at the end of S-phase by cyclin D1/Cdk4,6, 
which leads to the dissociation of E2F and Rb and transcrip-
tion of E2F target genes [177]. Upon exposure to genotoxic 
agents, the Cdk-inhibitor p21 is induced and abolishes Cdk-
mediated phosphorylation of Rb, which results in hypophos-
phorylation of Rb, sequestration of the E2F protein and cell 
cycle arrest at the G1/S boundary of the cell cycle [171]. 
  If the damage of the DNA is too severe, programmed cell 
death (apoptosis) can be initiated to eliminate potential haz-
ardous cells, which bear the risk of uncontrollable behavior 
or transmission of mutations to daughter cells. Apoptosis is a 
form of cell death that is characterized by specific morpho-
logical changes of the cell like overall shrinkage, chromatin 
condensation and fragmentation of genomic DNA [178]. 
Apoptosis can be initiated by different extracellular and in-
tracellular factors like UV-light or ionizing radiation, che-
motherapeutic drugs, by activation of death receptors or by 
reactive oxygen species. The apoptotic program can be 
started by two main pathways, an extrinsic one that is initi-
ated by binding of ligands to membrane-bound death recep-
tors and activation of caspase 8, and by an intrinsic one, that 
is initiated by mitochondrial membrane permeabilisation, 
release of cytochrome c from the intermembraneous space 
and activation of procaspase 9. Both pathways lead to activa-
tion of caspase 3, which initiates controlled degradation of 
the cell (Fig. 5) [reviewed in: 179].  
  Mitochondrial membrane permeabilisation is controlled 
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which belong to the Bcl-2 superfamily. Members of this 
family fall into three groups and all either stimulate or inhibit 
programmed cell death. Bcl-2, Bcl-XL and Mcl1 belong to 
the group of anti-apoptotic proteins while Bax and Bak are 
pro-apoptotic proteins. The third group is composed of the 
BH3-only proteins, which can be subdivided into “activa-
tors” and “de-repressors”. The activators (e.g. tBid) can di-
rectly interact with the pro-apoptotic effector proteins Bax 
and Bak and induce their oligomerization which leads to the 
formation of pores in the mitochondrial membrane. The de-
repressors (e.g. PUMA) act in a more indirect way on the 
activation of Bax and Bak as they bind to anti-apoptotic pro-
teins that guard Bax and Bak and force their release from the 
inactivating complex [reviewed in: 180].  
  p53 initiates apoptosis in response to DNA damage pri-
marily through transcriptional activation of genes encoding 
apoptotic factors such as Bax, PUMA or Noxa, which neu-
tralize anti-apoptotic proteins from the IAP family [169, 170, 
181]. However, a significant portion of the tumor suppressor 
has also been found in the cytoplasm, where it is also pre-
vented from degradation and contributes to the initiation of 
cell death. In response to DNA damage, cytoplasmic p53 
induces the oligomerization of Bax, Bak, VDAC and cyclo-
philin D, which triggers the permeabilisation of the mito-
chondrial membrane, resulting in the release of the pro-
apoptotic molecules cytochrome c, smac and AIF [182, 183]. 
The mechanism how p53 translocates to the mitochondria is 
not fully understood. Neither phosphorylation nor acetyla-
tion appears to contribute to this process. However, it has 
been suggested that this process may be triggered by Mdm2-
mediated monoubiquitination of p53 [184]. Once p53 has 
arrived at the mitochondrial membrane it is rapidly deubiq-
uitinated by the local mitochondrial HAUSP protein via  a 
stress-induced mitochondrial p53-HAUSP complex, creating 
the apoptotically active, non-ubiquitinated p53 protein [184]. 
CONCLUSIONS 
  The whole process of DNA repair, starting with the sens-
ing and recognition of a DNA strand break and finally result-
ing in the ligation of the loose ends, is accomplished by a 
very complex network of interacting proteins that is only 
incompletely understood. Efforts of more recent years show 
that a bunch of different players are involved in the DNA 
damage response. Moreover, there is more and more evi-
dence that many of the sensing, signaling and repair factors 
interact with each other. Other repair factors even contribute 
to several different signaling and repair pathways. Examples 
of such multitalented factors are the MRN complex or ATM, 
but also Brca1, H2AX, PARP-1, RAD18 or DNA-PKcs. But 
even though this complex network began to become clearer 
in more recent years, a lot of open questions are left, includ-
ing the exact sensing mechanism of DNA damage and the 
identity of all the proteins involved in this process, the com-
munication of the factors with each other and the basics of 
the choice between different repair pathways.  
  Defects in the key players of the DNA damage response 
can result in a very severe outcome like genomic instability 
and predisposition for cancers. However, while DNA repair 
is of utmost importance for healthy individuals, it can be 
counterproductive during cancer therapy, which frequently 
uses the implementation of DNA damage to kill tumors by 
apoptosis. Therefore, attempts are currently under way to 
inhibit DNA repair during cancer therapy by specifically 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Apoptosis signaling pathways. Apoptosis can be induced upon activation of death receptors (DR) at the membrane by binding of 
cognate ligands or after release of pro-apoptotic factors from mitochondria. Upon DR activation, the initiator-caspase-8 becomes activated, 
which activates a caspase-cascade, and cleaves the pro-apoptotic proteins Bid. The cleavage of Bid results in the formation of active tBid, 
which, in cooperation with Bax and Bak, forms pores in the outer mitochondrial membrane resulting in the release of cytochrome c, forma-
tion of the apoptosome and activation of caspase 9. Caspases 9 activates caspase 3 leading to the degradation of intracellular targets. The pro-
apoptotic proteins Bax and Bak can be inhibited by Bcl-2 and Puma. Besides its nuclear function p53 can become monoubiquitinated in a 
Mdm2-dependent manner, which leads to the translocation of p53 to mitochondria where it participates in mitochondrial membrane perme-
abilization and cytochrome c release. 194    Current Genomics, 2010, Vol. 11, No. 3  Oberle and Blattner 
targeting key proteins of the repair machinery. Along this 
line, several inhibitors targeting DNA-PK or ATM have 
been synthesized, which are currently tested for their appli-
cation in humans. A detailed understanding of the DNA re-
pair networks would help to identify further targets and 
greatly support the development of new drugs for the treat-
ment of cancer.  
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